2. GPCR/G Protein
  3. LPL Receptor
  4. Amiselimod

Amiselimod (MT-1303) is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimodis promising for research of autoimmune diseases.

For research use only. We do not sell to patients.

Amiselimod Chemical Structure

Amiselimod Chemical Structure

CAS No. : 942399-20-4

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Amiselimod:

Other Forms of Amiselimod:

Amiselimod Related Antibodies

Top Publications Citing Use of Products

View All LPL Receptor Isoform Specific Products:

View All Isoforms
LPAR1 LPAR2 LPAR3 LPAR5 S1PR1 S1PR2 S1PR3 S1PR4 S1PR5

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Amiselimod (MT-1303) is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimodis promising for research of autoimmune diseases[1][2][3][4].

In Vitro

Amiselimod (100 nM, 12 h) is converted into Amiselimod-P in HEK293 cells or primary HCMs (human cardiac myocytes) more slowly than Fingolimod (HY-11063) was converted into fingolimod-P[1].
Amiselimod-P (0.001-1000 nM) shows agonist activity at S1P1 receptor with an EC50 of 75 pM, and is more potent than at S1P4 and S1P5 receptors but has no distinct agonist activity at S1P2 or S1P3 receptors in human S1P receptor-expressing cells[1].
Amiselimod-P (0.001-1000 nM) increases G-protein-activated inwardly rectifying potassium (GIRK) current amplitude in a concentration-dependent manner, with an EC50 of 41.6 nM in human atrial myocytes[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Amiselimod Related Antibodies
In Vivo

Amiselimod (1 mg/kg, p.o.,) converts into Amiselimod-P which is lower in rat heart tissue than fingolimod-P, potentially contributing to the minimal cardiac effects [1].
Amiselimod (0.3-30 mg/kg, p.o., with a 6 day interval between vehicle and 0.3 mg/kg, 13 or 14 day intervals between dose levels of 0.3, 3 and 30 mg/kg) hydrochloride does not affect heart rate or ECG parameters in monkeys[1].
Amiselimod (0.3 mg/kg, p.o., daily, 3 days) decreases S1P1 expression on CD4+ T cells from mesenteric lymph nodes in C57BL/6 mice[3].
. Amiselimod (0.3 mg/kg, p.o., daily, 28 days) inhibits the development of colitis induced by adoptive transfer of CD4+CD45RBhigh T cells in SCID mice[3].
Amiselimod (0.3 mg/kg, p.o., daily, 3-4 weeks) reduces infiltration of Th1 and Th17 cells into the colon of colitis mic e induced by adoptive transfer of CD4+CD45RBhigh T cells [3].
Amiselimod (0.1-0.3 mg/kg, p.o., daily, 21 days) inhibits the development of chronic colitis with an efficacy comparable to that of an anti-mTNF-α mAb (250 μg/mouse) in adoptive transfer of CD4+CD45RBhigh T cells induced colitis mice[3].
Amiselimod (0.1-1 mg/kg, p.o., daily, 18 weeks) strongly inhibits the development of lupus nephritis in MRL/lpr mice[4].
Amiselimod (0.1-0.3 mg/kg, p.o., daily, 10 weeks) prevents progression of lupus nephritis in NZBWF1 Mice[4].
Amiselimod (0.3 mg/kg, p.o., daily, 13 weeks) reduces infiltration of T Cells into the kidneys of NZBWF1 mice[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Four male cynomolgus monkeys, Macaca fascicularis, 3-4 years old [1].
Dosage: 0.3, 3, 30 mg/kg
Administration: p.o., with a 6 day interval between vehicle and 0.3 mg/kg, 13 or 14 day intervals between dose levels of 0.3, 3 and 30 mg/kg.
Result: Had no effects on heart rate or ECG parameters, including PR interval, QRS duration, QT interval and QTc at doses up to 30 mg/kg
Did not affect blood pressure at doses up to 30 mg/kg.
Animal Model: Male C57BL/6 mice, aged 5 weeks[3].
Dosage: 0.3 mg/kg
Administration: p.o., daily, 3 days
Result: Decreased S1P1 expression on CD4+ T cells from mesenteric lymph nodes.
Animal Model: Immunodeficient SCID mice with chronic colitis induced by adoptive transfer of CD4+CD45RBhigh T cells from BALB/c mice[3].
Dosage: 0.1, 0.3 mg/kg
Administration: p.o., daily, 28 days
Result: Body weight remained higher than that in the control group from 4 days after cell transfer.
Body weight in the 0.3 mg/kg treated group was significantly higher than that in the control group from 17 days.
Clinical scores (sum of scores for hunching, wasting, colon thickening, and stool consistency) in the 0.1 and 0.3 mg/kg treated groups were 1.5 and 1.1.
Reduced inflammatory cell infiltrates, epithelial hyperplasia and mucin depletion from goblet cells in the colon at 0.3 mg/kg.
Animal Model: Immunodeficient SCID mice with chronic colitis induced by adoptive transfer of CD4+CD45RBhigh T cells from BALB/c mice[3].
Dosage: 0.1, 0.3 mg/kg
Administration: p.o., daily, 21 days, the anti-mTNF-α mAb (250 μg/mouse) was intraperitoneally injected on days 7 and 21.
Result: Increased body weight from day 15 comparable to anti-mTNF-α mAb-treated groups.
Clinical scores in the 0.1 and 0.3 mg/kg treated groups were 1.1 and 0.6 and anti-mTNF-α mAb-treated group was 1.2.
Inhibited the development of chronic colitis with an efficacy comparable to that of an anti-mTNF-α mAb (250 μg/mouse).
Animal Model: Immunodeficient SCID mice with chronic colitis induced by adoptive transfer of CD4+CD45RBhigh T cells from BALB/c mice[3].
Dosage: 0.3 mg/kg
Administration: p.o., daily, 3-4 weeks
Result: Significantly reduced the number of infiltrating lymphocytes and CD4+ T cells.
Decreased the number of IFN-γ- and IL-17-producing CD4+ T cells in the lamina propria.
Produced significantly less IFN-γ and IL-17 than those from vehicle-treated mice.
Animal Model: MRL/lpr mice at 8 weeks of age without proteinuria[4].
Dosage: 0.1, 0.3, 1 mg/kg
Administration: p.o., daily, 18 weeks
Result: No mice treated at doses greater than 0.3 mg/kg developed lupus nephritis during the study period.
Reduced this infiltration of T cells into the kidneys.
Inhibited the development of lymphadenopathy and splenomegaly.
Decreased the number of T cells,CD4 T cells, B cells, and MRL/lpr-mouse-specific abnormal T cells.
Animal Model: NZBWF1 mice at 30 weeks of age without proteinuria[4].
Dosage: 0.1, 0.3 mg/kg
Administration: p.o., daily, 10 weeks
Result: Mean proteinuria scores remained lower than those in the control group.
Attenuated the severity of several histological changes including mesangial expansion, glomerular sclerosis, and interstitial infiltrates.
Animal Model: NZBWF1 mice at 41 weeks of age without proteinuria[4].
Dosage: 0.3 mg/kg
Administration: p.o., daily, 13 weeks
Result: Reduced the number of infiltrating T cells, CD4 T cells, CD8 T cells, and CD4-CD8- double-negative (DN) T cells.
Decreased B cell counts.
Molecular Weight

377.44

Formula

C19H30F3NO3
CAS No.
SMILES

FC(F)(C1=CC(CCC(CO)(CO)N)=CC=C1OCCCCCCC)F
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Amiselimod Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Amiselimod942399-20-4MT-1303MT1303MT 1303LPL ReceptorLysophospholipid Receptororally activeS1P1bradycardia effectsS1P5S1P4autoimmune diseasesHCMshuman cardiac myocyteschronic colitislupus nephritisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Amiselimod
Cat. No.:
HY-16734
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.